Merck & Co., Inc.





Market Closed - Nyse 04:00:01 2024-02-23 pm EST 5-day change 1st Jan Change
129.4 USD +0.15% Intraday chart for Merck & Co., Inc. +1.30% +18.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Merck Says EMA Committee Endorses Keytruda Combination for Resectable Lung Cancer MT
Merck's Lung Cancer Therapy Receives Positive Opinion for EU Approval MT
Merck: positive CHMP opinion for Keytruda in NSCLC CF
Merck Gets CHMP Backing for Keytruda in Certain Non-Small Cell Lung Cancer DJ
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence CI
Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says RE
Merck's Keytruda Gets FDA's Priority Review for Endometrial Carcinoma MT
Merck: priority review in endometrial cancer. CF
Merck Gets Speedy FDA Review for New Keytruda Uterine Cancer Indication DJ
FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma CI
Merck & Co. Insider Sold Shares Worth $29,538,998, According to a Recent SEC Filing MT
Merck & Co. Insider Sold Shares Worth $4,805,521, According to a Recent SEC Filing MT
Soros Fund Management Llc Dissolves Share Stake In General Motors, Apple, Maplebear; Takes Share Stake In Merck RE
Putin says Russia is close to creating cancer vaccines RE
Merck & Co. Insider Sold Shares Worth $1,845,083, According to a Recent SEC Filing MT
Merck Gets Health Canada's Approval of Keytruda Combination to Treat Gastric Cancer MT
Merck: new approval for Keytruda in Canada CF
Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma CI
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination MT
US Senate Democrats grill pharma CEOs on drug prices RE
Merck Canada Collaborates With Vector Institute on AI in Healthcare MT
Merck & Co. Insider Sold Shares Worth $2,411,111, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Merck to Acquire Elanco Animal Health's Aqua Business in $1.3 Billion Deal MT
Sector Update: Health Care Stocks Advance Monday Afternoon MT
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
129.4 USD
Average target price
133.6 USD
Spread / Average Target
1st Jan change Capi.
+18.74% 328 B $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
+0.42% 155 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse
  4. News Merck & Co., Inc.
  5. US Senate Health Committee Members Ask Johnson & Johnson, Merck, Bristol-Myers Squibb CEOs to Testify on Drug Pricing
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance